Latest Breaking News On - Parke davis pharmaceuticals - Page 2 : comparemela.com

Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023

Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeMonica kozlowskiMiriam portmanBarry kommSimon jenkinsElizabeth attiasEli lillyDavid portmanPaul plourdeLigand pharmaceuticals incTranslational committeeParke davis pharmaceuticalsSermonixsermonix pharmaceuticals incSermonix pharmaceuticals incSermonix pharmaceuticals

Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene

Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesPaul plourdeGlenn garmontlifesci advisorsmanagingMassimo cristofanilliElizabeth attiasMiriam portmanSysmex inostics oncobeamSimon jenkinsDavid portmanBarry kommSermonixsermonix pharmaceuticals incLigand pharmaceuticals incParke davis pharmaceuticalsSermonix pharmaceuticals incInternational society of liquid biopsy

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research Translating Knowledge Into Practice - read this article along with other careers information, tips and advice on BioSpace

United statesPaul plourdeMiriam portmanSimon jenkinsDavid portmanElizabeth attiasBarry kommGlenn garmontLigand pharmaceuticals incJapanese cancer associationAmerican association for cancer researchBreakthroughs in cancer researchParke davis pharmaceuticalsSermonix pharmaceuticals incDuke universityInvestor relations corporate communications

Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated

United statesSan antonioPaul plourdeElizabeth attiasMonica kozlowskiGlenn garmontMiriam portmanSimon jenkinsDavid portmanBarry kommLigand pharmaceuticals incSociety lifestyleHealthcare pharmaceuticals industryParke davis pharmaceuticalsSermonix pharmaceuticals incHenryb gonzalez convention center

Sermonix Pharmaceuticals Announces Four Abstracts Accepted

COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative.

United statesSan antonioPaul plourdeElizabeth attiasMonica kozlowskiGlenn garmontMiriam portmanSimon jenkinsDavid portmanBarry kommLigand pharmaceuticals incParke davis pharmaceuticalsSermonix pharmaceuticals incHenryb gonzalez convention centerDuke universityInvestor relations corporate communications